862129-81-5

Basic information

• Product Name: 3,6-Dihydro-2H-thiopyran-4-ylboronic acid pinacol ester
• Synonyms: 3,6-Dihydro-2H-thiopyran-4-ylboronic acid pinacol ester;4,4,5,5-tetramethyl-2-(3,5-dihydro-2H-thiopyran-4-yl)-1,3,2-dioxaborolane;2H-Thiopyran, 3,6-dihydro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-;6-dihydro-2H-thiopyran-4-yl)-4;2-(3,6-dihydro-2H-thiopyran-4-yl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane;3,6-Dihydro-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-2H-thiopyran;3,6-Dihydrothiopyran-4-boronic acid pinacol ester, 98%;3-hydroxy-2,3-dimethylbutan-2-yl hydrogen (3,6-dihydro-2H-thiopyran-4-yl)boronate
• CAS NO: 862129-81-5
• Molecular Formula: C₁₁H₁₉BO₂S
• Molecular Weight: 226.14
• EINECS: 1592732-453-0
• Product Categories: Organoborons;Organic boronic acid
• Mol File: 862129-81-5.mol

Chemical Properties

• Boiling Point: 281.1°C at 760 mmHg
• Flash Point: 123.8°C
• Appearance: /Solid
• Density: 1.02g/cm³
• Vapor Pressure: 0.0062mmHg at 25°C
• Refractive Index: 1.484
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 3,6-Dihydro-2H-thiopyran-4-ylboronic acid pinacol ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6-Dihydro-2H-thiopyran-4-ylboronic acid pinacol ester(862129-81-5)
• EPA Substance Registry System: 3,6-Dihydro-2H-thiopyran-4-ylboronic acid pinacol ester(862129-81-5)

Safety Data

• Hazardous Substances Data: 862129-81-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3,6-Dihydro-2H-thiopyran-4-ylboronic acid pinacol ester is used as a reagent in organic synthesis for the formation of carbon-carbon and carbon-heteroatom bonds. Its ability to participate in cross-coupling reactions makes it a valuable component in creating complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3,6-Dihydro-2H-thiopyran-4-ylboronic acid pinacol ester is used as a precursor in the synthesis of biologically active compounds. Its potential applications in medicinal chemistry are attributed to the biological activities and therapeutic potential of boronic acid derivatives, which are being studied for their use in developing new drugs.
Used in Suzuki-Miyaura Coupling Reactions:
3,6-Dihydro-2H-thiopyran-4-ylboronic acid pinacol ester is employed as a key component in Suzuki-Miyaura coupling reactions, which are widely used in the synthesis of biaryl compounds. These reactions are crucial for the production of pharmaceuticals, agrochemicals, and advanced materials that contain biaryl structures.

InChI:InChI=1/C11H21BO2S/c1-10(2)11(3,4)14-12(13-10)9-5-7-15-8-6-9/h9H,5-8H2,1-4H3

Upstream product

• 73183-34-3 bis(pinacol)diborane 
• 1072-72-6 Tetrahydrothiopyran-4-one 
• 181180-42-7 3,6-dihydro-2H-thiopyran-4-enol trifluoromethanesulfonate 
• 121-43-7 Trimethyl borate 
• 126-30-7 2,2-Dimethyl-1,3-propanediol 
• 76-09-5 2,3-dimethyl-2,3-butane diol 

Downstream Products

• 862129-83-7 1-(2-{4-[2-(3,6-dihydro-2H-thiopyran-4-yl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine 
• 1227068-55-4 4-(3-(3,6-dihydro-2H-thiopyran-4-yl)pyrazin-2-yloxy)-N-methoxy-N-methylbenzamide 
• 1370535-33-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-thiopyran 1,1-dioxide 

Relevant articles and documents

Synthesis of Functionalized [3], [4], [5] and [6]Dendralenes through Palladium-Catalyzed Cross-Couplings of Substituted Allenoates

A mild method for the synthesis of highly functionalized [3]–[6]dendralenes is reported, representing a general strategy to diversely substituted higher homologues of the dendralenes. The methodology utilizes allenoates bearing various substitution patter

Method for synthesizing 3, 6-dihydro-2H-pyrazine (thiazine) furan-4-boric acid ester

The invention discloses a method for synthesizing 3, 6-dihydro-2H-pyrazine (thiazine) furan-4-boric acid ester. According to the method, tetrahydropyrazole (thiazine) furan-4-ketone serves as the raw material, generates hydrazone with p-toluenesulfonhydrazide, then reacts with NBS/organic alkali to generate alkenyl bromide and next forms Grignard reagent with magnesium metal, after the Grignard reagent is formed, boron reagent is added for a reaction, and the 3, 6-dihydro-2H-pyrazine (thiazine) furan-4-boric acid ester is obtained. By means of the method, ultralow temperature, column chromatography and palladium catalyzed coupling in a literature method are avoided, raw materials are easy to obtain, cost is low, conditions are mild, and the method has potential industrial application and amplification prospect.

BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK activated protein kinase. The compounds of the present invention may be usef

PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS

Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety

Structure-activity relationship studies are described, which led to the discovery of novel selective estrogen receptor modulators (SERMs) for the potential treatment of uterine fibroids. The SAR studies focused on limiting brain exposure and were guided by computational properties. Compounds with limited impact on the HPO axis were selected using serum estrogen levels as a biomarker for ovarian stimulation.

Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia

The present invention relates to a method of treating schizophrenia which comprises administering a therapeutically effective amount of a compound of formula I wherein R1, R2, and R3 are as defined in the specification or to pharmaceutically active acid-addition salts thereof.

SELECTIVE ESTROGEN RECEPTOR MODULATORS

The present invention relates to a selective estrogen receptor modulator of formula I: or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma.